Terminated PHASE2 INTERVENTIONAL 2-arm NCT01838499

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Sponsor: AstraZeneca

Conditions Hidradenitis Suppurativa

Interventions MEDI8968 Saline

Updated 12 times since 2017 Last updated: Jul 21, 2016 Started: May 31, 2013 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

At the planned IA for decision making, no evidence was demonstrated of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.

This PHASE2 trial investigates Hidradenitis Suppurativa and is currently terminated or withdrawn. AstraZeneca leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE2
Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE2

▶ Show 7 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE2
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE2
May 2018 — Jun 2018 [monthly]

Terminated PHASE2
Aug 2017 — May 2018 [monthly]

Terminated PHASE2
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Covance
ICON plc
PHT Corporation

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Atlanta, United States , Bakersfield, United States , Chapel Hill, United States , Evansville, United States , Forest Hills, United States , Fremont, United States , Hershey, United States , High Point, United States , Indianapolis, United States and 17 more locations